65,437 trials
Immune Thrombocytopenic Purpura
Primary: Number of Participants With Stable Platelet Response of at Least 50,000/µL — 9; 1 Participants — p=0.1519
Dengue Fever
Primary: Number of Subjects With Adverse Events Within the 28 Day Follow-up — 10; 9; 10; 14 Participants
Scleroderma, Systemic
Primary: Change From Baseline in Modified Rodnan Skin Score (mRSS) to Week 52 — -2.088; -0.769 score on a scale — p=0.0815
Abdominal Aortic Aneurysm · Iliac Aneurysm · Internal Iliac Aneurysm
Primary: Freedom From Aneurysm Rupture — 0 Participants
Infections, Meningococcal
Primary: Number of Subjects With Vaccine Response for Serum Bactericidal Assay Using Rabbit Complement Against Neisseria Meningitides Serogroup A, C, W-135 and Y (rSBA-MenA…
Smoking · Nicotine Addiction · Surgery
Primary: Smoking Status on the Day of Surgery (48-hour Point-prevalence Abstinence), by Self-report and Confirmed With Exhaled Carbon Monoxide (CO) — 2; 3 Participants
Poliomyelitis · Tetanus · Acellular Pertussis
Primary: Number of Seroprotected Subjects Against Diphteria (D) and Tetanus (T) Antigens — 105; 106; 105; 106 Participants
Diabetes Mellitus, Type 2
Primary: Time to the First Occurrence of Any of the Following Adjudication-confirmed Components of the Primary Composite Endpoint 3-point Major Adverse Cardiovascular (CV) Events…
Cannabis Use Disorder
Primary: Self-report Instruments to Measure Cannabis Use — 26.72; 5.256 Inhalations of Cannabis Per Day
Coronary Artery Disease
Primary: Among Patients With an Appropriate ICD Therapy (Shock or ATP) for Ventricular Tachycardia or Fibrillation, the Number of Patients Who Have Characterized ST Segment…
Type 2 Diabetes
Primary: Baseline Characteristics of Adults (as Measured by Demographics) With a Recorded Diagnosis of T2DM Starting Index Prescriptions in the UK — 5.45; 1.76; 1.44; 3.03…
Healthy
Primary: Area Under the Plasma Concentration-Time Curve From Time Zero to the Last Sampling Time (AUC0-t) at Concentration at or Above Lower Limit of Quantitation (LLOQ) of…
Patients With CLL Relapsing After an Initial Response (CR, PR ≥ 6 Months) Following no More Than Two Prior Treatment Lines; or · Patients With CLL Refractory (SD, PD or CR/PR < 6 Months) Following no More Than Two Prior Treatment Lines
Primary: Number of Participants Contributing to the Overall Response Rate — 34 participants
Acute Bronchiolitis
Primary: Respiratory Assessment Change Score (RACS) — 1.68; 1.70 score on a scale
Healthy
Primary: Plasma AUCinf for PF-06463922 Given Alone and With Rifampin — 8766; 1299 nanogram (ng)*hr/ millilitre (mL)